David Petch

CEO CSO @Utr Biotech Emerge Excel Exploit Evolve

Type 1 diabetes cost 1.4 trillion USD annually to treat the secondary symptoms associated with this disease (Alzheimer’s disease, neuropathy, Cardiovascular disease, cancer, NASH/NAFLD, amputations, ulcers, microcirculation etc). We have a protein additive to add to current insulin formulations to minimize/prevent these complications. We have a team of six different researchers with completed budgets to start upon funding. The budget is 2.2 million USD over 36 months, with Mitacs to Fund at a rate of 1.2x what we receive.